Officers & Council
Dates & Locations
50th Annual Meeting
Submit Proposals / Abstracts
Plenaries / Workshops
Neuropsychopharmacology - 5th Generation of Progress
Psychopharmacology - 4th Generation of Progress
Oral History Books
Applications & Nominations
Programs & Initiatives
Initiatives & Task Force Reports
Awards & Grants
Oral History of Neuropsychopharmacology
Public & Media Resources
The Importance of Research
Science Discussion Forum
Members in the Scientific News
Applications & Nominations
A - E
F - L
M - R
S - Z
Toni S. Shippenberg, 1955-2012
Toni Shippenberg’s contributions to the fields of Neuroscience and Neuropharmacology over the years were outstanding and are reflected by the high esteem she was held in by colleagues within NIH as well as throughout the United States and abroad.
Arthur Yuwiler, 1927-2012
Arthur Yuwiler once wrote that “in contrast to claims that art and science are two separate antithetical ways of approaching the world … they are, at base, the same”. He was the best example of such a synthesis, a true Renaissance-type humanist, brilliant scientist, creative artist and world traveler.
Wylie Vale, 1941-2012
Wylie W. Vale Jr., an eminent endocrinologist who helped identify the hormones through which the brain governs basic bodily functions and who was involved in a combative race for the Nobel Prize.
Charles R. Schuster, 1930-2011
As Director of the National Institute for Drug Abuse at the National Institutes of Health, Dr. Schuster appreciated the complexities of the problems and how effective administration could help make the problems easier to grasp and deal with; the staff of the Institute could sense his enjoyment. He avoided many pitfalls, and never came to think that he would solve the public’s problem. Throughout the rest of his career, he often remarked on the perspective and excitement that the Directorship afforded him.
Saul M. Schanberg
Dr. Schanberg is globally recognized for his ground-breaking research on the importance of touch in normal growth and development, finding that specific types of touch led to better health and shorter hospital stays for premature infants. His discoveries changed the way hospitals and clinics all over the world care for premature infants.
Joseph J. Schildkraut, 1934-2006
Joseph J. Schildkraut, M.D., is known for his work from the early- to mid-1960s that set the stage for psychopharmacological research in affective disorders for the years since.
Mogens Schou, 1918-2005
Mogens Schou, M.D., had a long and distinguished career dedicated to research on therapeutic uses of lithium rooted in his deep concern for all patients with mood disorders.
David Segal, 1942-2005
David Segal, Ph.D., was nationally and internationally known as an expert and a creative scientific leader in the study of the long-term effects of drugs on behavior and the neurochemical mechanisms of adaptation.
Lewis S. Seiden, 1934-2007
Lewis S. Seiden, Ph.D., is known as a pioneer in the fields of behavioral pharmacology and amphetamine neurotoxicology. He was a Professor Emeritus of pharmacological and physiological sciences and of psychiatry at the University of Chicago at the time of his death.
Robert Bruce Sloane, 1923-2007
Robert Bruce Sloane, M.D., published widely including papers with Stanley Cobb, Ted Sourkes (which was one of the earliest papers on catecholamines and mental illness), and Murray Saffrin on steroids all in the late 50s.
Jon M. Stolk
Jon M. Stolk, Ph.D, M.D., focused his research on the characteristics of the synthetic enzymes in the norepinephrine and epinephrine pathways.
A. Arthur Sugerman, 1929-2007
A. Arthur Sugerman, M.D., published widely on the use of antipsychotic drugs in the treatment of schizophrenia as well as on EEG studies and addiction.
John Tallman, 1947-2006
John Tallman, Ph.D., was a pioneer of the properties of the GABA neurotransmitter receptor using pharmacological and molecular biological probes. In 2001, he became the president and CEO of Helicon Therapeutics, Inc., a biotech company with a focus on functional genomics of memory and therapeutics to enhance memory consolidation.
Maharaj K. Ticku, 1948-2007
In addition to his research contributions to molecular neurobiology, Dr. Raj Ticku was a critical leader at the University of Texas Health Science Center in San Antonio. He was an excellent teacher and played a key role in the recruitment of new talent to the Center and led many faculty and chair searches.
Gary Tollefson 1951-2009
During his academic career, Dr. Tollefson's work focused primarily on antidepressants and anxiolytic drugs. He contributed important research on interaction of antidepressants and other psychotropic drugs with muscarinic-cholinergic receptors, predicting their propensity to produce anticholinergic side effects.
William J. Turner, 1907-2006
William J. Turner, M.D., was a first-generation psychiatric researcher, being almost alone in focusing on the biological cause of mental illness.
Francis J. White, 1952-2006
Francis J. White, Ph.D., a leader in the neurobiology of addiction, his research endeavors were supported continuously by NIDA, including a prestigious MERIT award.
Norm Weiner, M.D., best known for his pioneering work on catecholamine synthesis, storage, and release, was equally committed to scientific research and to education, making enormous contributions to the development of leaders and to science policy.
Elizabeth A. Young
Dr. Young was an internationally renowned biological psychiatrist who conducted seminal work on stress biology and its role in severe depression and other mood disorders. She was elected to the ACNP in 1996.
Note: after 3 unsucessful attempts your account will be locked. Please contact the executive office at
Forgot your user name or password?
© 2008 American College of Neuropsychopharmacology
5034-A Thoroughbred Lane
Brentwood, TN 37027